Novartis Sales Growth Guidance: 5% a Year to 2031 as Kesimpta Peak Rises to $8B
Novartis guides to 5% annual sales growth through 2031, down from 5-6%, while raising peak sales for Kesimpta, Scemblix and Leqvio.
Novartis guides to 5% annual sales growth through 2031, down from 5-6%, while raising peak sales for Kesimpta, Scemblix and Leqvio.